US 11,787,803 B2
Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
Shawn E. R. Schiller, Haverhill, MA (US); Torsten Herbertz, Stow, MA (US); Hongbin Li, Madison, CT (US); Bradford Graves, Nutley, NJ (US); Steven Mischke, Waltham, MA (US); Angela V. West, Franklin, MA (US); Jennifer R. Downing, Clinton, MA (US); and Anna Ericsson, Shrewsbury, MA (US)
Assigned to Forma Therapeutics, Inc., Watertown, MA (US)
Filed by FORMA Therapeutics, Inc., Watertown, MA (US)
Filed on Feb. 10, 2022, as Appl. No. 17/669,135.
Application 17/669,135 is a continuation of application No. 16/647,478, granted, now 11,292,791, previously published as PCT/US2018/051235, filed on Sep. 14, 2018.
Claims priority of provisional application 62/692,593, filed on Jun. 29, 2018.
Claims priority of provisional application 62/559,436, filed on Sep. 15, 2017.
Prior Publication US 2022/0169647 A1, Jun. 2, 2022
Int. Cl. C07D 471/04 (2006.01); C07D 519/00 (2006.01); A61P 35/00 (2006.01)
CPC C07D 471/04 (2013.01) [A61P 35/00 (2018.01); C07D 519/00 (2013.01)] 20 Claims
 
1. A compound of formula (I-h):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R1 is —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —C3-C8cycloalkyl, —C4-C8cycloalkenyl, heterocyclyl, heteroaryl, aryl, —OR5, —N(R5)2, or —NHR5;
R4 and R4′ are each independently —H, halogen, —OH, —CN, or —NH2;
each R5 is independently —C1-C6alkyl, —C3-C8cycloalkyl, heterocyclyl, aryl, or heteroaryl;
R6 and R7 are each independently, at each occurrence, —C1-C6alkyl, —C3-C8cycloalkyl, —C4-C8cycloalkenyl, heterocyclyl, aryl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, —OH, halogen, oxo, —CN, —SR8, —OR8, —(CH2)n—OR8, —NHR8, NR8R9, —S(O)2NR8R9, —S(O)2R8′, —C(O)R8′, —C(O)OR8, —C(O)NR8R9, —NR8C(O)R9′, —NR8S(O)2R9′, —S(O)R8′, —S(O)NR8R9, or —NR8S(O)R9′, wherein each alkyl, cycloalkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R10;
R8 and R9 are each independently, at each occurrence, —H, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —C3-C8cycloalkyl, —C4-C8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R10 or R11; or
R8 and R9 may combine with the atom to which they are both attached to form a —C3-C8cycloalkyl, —C4-C8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl, wherein the formed —C3-C8cycloalkyl, —C4-C8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R10 or R11;
R8′ and R9′ are each independently, at each occurrence, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —C3-C8cycloalkyl, —C4-C8cycloalkenyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more R10 or R11; or
R8′ and R9′ may combine with the atom to which they are both attached to form a —C3-C8cycloalkyl, —C4-C8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl, wherein the formed —C3-C8cycloalkyl, —C4-C8cycloalkenyl, spirocycloalkyl, spiroheterocyclyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more R10 or R11;
R10 and R11 are each independently, at each occurrence, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —C3-C8cycloalkyl, —C4-C8cycloalkenyl, heterocyclyl, heteroaryl, aryl, —OH, halogen, oxo, —NO2, —CN, —NH2, —OC1-C6alkyl, —OC3-C6cycloalkyl, —Oaryl, —Oheteroaryl, —NHC1-C6alkyl, —N(C1-C6alkyl)2, —S(O)2NH(C1-C6alkyl), —S(O)2N(C1-C6alkyl)2, —S(O)2C1-C6alkyl, —C(O)C1-C6alkyl, —C(O)NH2, —C(O)NH(C1-C6alkyl), —C(O)N(C1-C6alkyl)2, —C(O)OC1-C6alkyl, —N(C1-C6alkyl)SO2C1-C6alkyl, —S(O)(C1-C6alkyl), —S(O)N(C1-C6alkyl)2, or —N(C1-C6alkyl)S(O)(C1-C6alkyl), wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heteroaryl, or aryl is optionally substituted with one or more —R12;
wherein any two R10 or any two R11, when on non-adjacent atoms, can combine to form a bridging cycloalkyl or heterocyclyl;
wherein any two R10 or any two R11, when on adjacent atoms, can combine to form a cycloalkyl, heterocyclyl, aryl or heteroaryl;
R12 is independently, at each occurrence, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, —C3-C8cycloalkyl, —C4-C8cycloalkenyl, heterocyclyl, heteroaryl, aryl, —OH, halogen, oxo, —NO2, —CN, —NH2, —OC1-C6alkyl, —NHC1-C6alkyl, —N(C1-C6alkyl)2, —S(O)2NH(C1-C6alkyl), —S(O)2N(C1-C6alkyl)2, —S(O)2C1-C6alkyl, —C(O)C1-C6alkyl, —C(O)NH2, —C(O)NH(C1-C6alkyl), —C(O)N(C1-C6alkyl)2, —C(O)OC1-C6alkyl, —N(C1-C6alkyl)SO2C1-C6alkyl, —S(O)(C1-C6alkyl), —S(O)N(C1-C6alkyl)2, or —N(C1-C6alkyl)S(O)(C1-C6alkyl); and
n is an integer from 1 to 4.